<DOC>
	<DOC>NCT00853606</DOC>
	<brief_summary>This open-label study is being conducted to evaluate the long-term safety, tolerability, and efficacy of avanafil in men with mild to severe erectile dysfunction. Approximately 400 subjects will be enrolled and treated with avanafil for up to 52 weeks.</brief_summary>
	<brief_title>Long-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<criteria>Successfully completed the entire treatment period in a qualifying study (TA301 [NCT00790751] or TA302 [NCT00809471]); Demonstrated compliance with the study protocol, including drug administration, diary completion, and scheduled study visits, during the qualifying trial; Made at least 4 attempts at intercourse during the last treatment period of the qualifying trial; Agree to make at least 4 attempts at intercourse each month through the course of this study; Agree not to use any other treatments for erectile dysfunction during participation in this study. Provide written informed consent; Willing and able to comply with scheduled study visits, treatment plan, laboratory tests, and other study procedures. Subjects who, in the opinion of the investigator, have developed one or more comorbidities during the qualifying study that would pose a safety concern to their continuation on treatment in study TA314; Subjects requiring treatment with an excluded medication.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>ED</keyword>
	<keyword>Erectile Dysfunction</keyword>
	<keyword>Dysfunction</keyword>
	<keyword>Erectile</keyword>
</DOC>